Literature DB >> 23723240

Accelerating next-generation vaccine development for global disease prevention.

Wayne C Koff1, Dennis R Burton, Philip R Johnson, Bruce D Walker, Charles R King, Gary J Nabel, Rafi Ahmed, Maharaj K Bhan, Stanley A Plotkin.   

Abstract

Vaccines are among the greatest successes in the history of public health. However, past strategies for vaccine development are unlikely to succeed in the future against major global diseases such as AIDS, tuberculosis, and malaria. For such diseases, the correlates of protection are poorly defined and the pathogens evade immune detection and/or exhibit extensive genetic variability. Recent advances have heralded in a new era of vaccine discovery. However, translation of these advances into vaccines remains impeded by lack of understanding of key vaccinology principles in humans. We review these advances toward vaccine discovery and suggest that for accelerating successful vaccine development, new human immunology-based clinical research initiatives be implemented with the goal of elucidating and more effectively generating vaccine-induced protective immune responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23723240      PMCID: PMC4026248          DOI: 10.1126/science.1232910

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  80 in total

Review 1.  The value of vaccination: a global perspective.

Authors:  Jenifer Ehreth
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

2.  Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines.

Authors:  J E SALK; U KRECH; J S YOUNGNER; B L BENNETT; L J LEWIS; P L BAZELEY
Journal:  Am J Public Health Nations Health       Date:  1954-05

Review 3.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

4.  Vaccine R&D success rates and development times.

Authors:  M M Struck
Journal:  Nat Biotechnol       Date:  1996-05       Impact factor: 54.908

5.  Live, attenuated mumps-virus vaccine.

Authors:  M R Hilleman; E B Buynak; R E Weibel; J Stokes
Journal:  N Engl J Med       Date:  1968-02-01       Impact factor: 91.245

6.  Development and evaluation of the Moraten measles virus vaccine.

Authors:  M R Hilleman; E B Buynak; R E Weibel; J Stokes; J E Whitman; M B Leagus
Journal:  JAMA       Date:  1968-10-14       Impact factor: 56.272

7.  Attenuation of RA 27-3 rubella virus in WI-38 human diploid cells.

Authors:  S A Plotkin; J D Farquhar; M Katz; F Buser
Journal:  Am J Dis Child       Date:  1969-08

Review 8.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

9.  Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data.

Authors:  Denise L Doolan; Scott Southwood; Daniel A Freilich; John Sidney; Norma L Graber; Lori Shatney; Lolita Bebris; Laurence Florens; Carlota Dobano; Adam A Witney; Ettore Appella; Stephen L Hoffman; John R Yates; Daniel J Carucci; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-28       Impact factor: 11.205

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  119 in total

1.  Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.

Authors:  Onofrio Zirafi; Kyeong-Ae Kim; Nadia R Roan; Silvia F Kluge; Janis A Müller; Shibo Jiang; Benjamin Mayer; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

Review 2.  Pediatric Vaccine Adjuvants: Components of the Modern Vaccinologist's Toolbox.

Authors:  David J Dowling; Ofer Levy
Journal:  Pediatr Infect Dis J       Date:  2015-12       Impact factor: 2.129

Review 3.  Computational tools for epitope vaccine design and evaluation.

Authors:  Linling He; Jiang Zhu
Journal:  Curr Opin Virol       Date:  2015-03-31       Impact factor: 7.090

Review 4.  Systems-level analysis of innate immunity.

Authors:  Daniel E Zak; Vincent C Tam; Alan Aderem
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

Review 5.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

6.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 7.  Proteomic contributions to our understanding of vaccine and immune responses.

Authors:  Allison C Galassie; Andrew J Link
Journal:  Proteomics Clin Appl       Date:  2015-09-10       Impact factor: 3.494

8.  Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.

Authors:  Lawrence W Dick; John T Mehl; John W Loughney; Anna Mach; Richard R Rustandi; Sha Ha; Lan Zhang; Craig T Przysiecki; Lance Dieter; Van M Hoang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

10.  Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.

Authors:  J J Taylor; M Laudenbach; A M Tucker; M K Jenkins; M Pravetoni
Journal:  J Immunol Methods       Date:  2014-01-23       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.